Literature DB >> 9000601

Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours.

K Fizazi1, F Farhat, C Theodore, O Rixe, A Le Cesne, E Comoy, T Le Chevalier.   

Abstract

Seven consecutive patients with intra-abdominal desmoplastic small round-cell tumours were screened at presentation for carcinoembryonic antigen (CEA), Ca19-9, Ca15-3, Ca125, alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and neuron-specific enolase (NSE). Initially elevated tumour markers were used to monitor therapy and follow-up. Tumour marker assays were all in the normal range, with the exception of Ca125 and NSE. The Ca125 level was initially high in six of the seven patients (86%) with a median value of 200 U ml-1 and a range of 22-735 U ml-1. The NSE value was elevated before therapy in three of the five patients (60%) for whom assay results were available, with a median of 19 ng ml-1 and a range of 6.8-37.5 ng ml-1 . Ca1 25 normalized in five out of six cases and NSE always normalized during chemotherapy, but neither of these two tumour markers correlated specifically with response, as only one patient experienced a partial response, five tumour stabilization and the remaining patient tumour progression. At progression, Ca125 was again elevated in two out of four cases several weeks before clinical relapse and NSE in only one out of three cases. Ca125 and NSE are frequently raised in the serum of patients with intra-abdominal desmoplastic small round-cell tumours before therapy, but are not reliable monitors of the course of the disease. However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000601      PMCID: PMC2222692          DOI: 10.1038/bjc.1997.12

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Case 2. Desmoplastic small cell tumor with divergent differentiation.

Authors:  W L Gerald; J Rosai
Journal:  Pediatr Pathol       Date:  1989

2.  Malignant small-cell epithelial tumor of the peritoneum coexpressing mesenchymal-type intermediate filaments.

Authors:  N G Ordóñez; R Zirkin; R E Bloom
Journal:  Am J Surg Pathol       Date:  1989-05       Impact factor: 6.394

3.  Elevation of CA 125 in patients with benign and malignant ascites.

Authors:  J F Bergmann; J M Bidart; M George; M Beaugrand; V G Levy; C Bohuon
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

4.  Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma. A prospective study in an unselected series.

Authors:  E Nõu; L Steinholtz; J Bergh; K Nilsson; S Påhlman
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

5.  Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma.

Authors:  N van Zandwijk; E Jassem; J M Bonfrer; H van Tinteren
Journal:  Eur J Cancer       Date:  1990-03       Impact factor: 9.162

6.  Intra-abdominal neuroectodermal tumour of childhood with divergent differentiation.

Authors:  S Variend; M Gerrard; P D Norris; J R Goepel
Journal:  Histopathology       Date:  1991-01       Impact factor: 5.087

7.  Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals.

Authors:  W L Gerald; H K Miller; H Battifora; M Miettinen; E G Silva; J Rosai
Journal:  Am J Surg Pathol       Date:  1991-06       Impact factor: 6.394

8.  Intraabdominal desmoplastic small-cell tumors with divergent differentiation. Observations on three cases of childhood.

Authors:  F Gonzalez-Crussi; S E Crawford; C C Sun
Journal:  Am J Surg Pathol       Date:  1990-07       Impact factor: 6.394

9.  Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer.

Authors:  M Diez; F J Cerdàn; M D Ortega; A Torres; A Picardo; J L Balibrea
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

10.  Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.

Authors:  P W Johnson; S P Joel; S Love; M Butcher; M R Pandian; L Squires; P F Wrigley; M L Slevin
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more
  6 in total

1.  Beware of immunohistochemistry--report of a cytokeratin-, desmin- and INI-1-negative pelvic desmoplastic small round cell tumor in a 51 year old woman.

Authors:  Gwyneth St Soon; Fredrik Petersson
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Metastatic desmoplastic small round cell tumor controlled by an anthracycline-based regimen: review of the role of chemotherapy.

Authors:  H Mrabti; W Kaikani; N Ahbeddou; H Abahssain; B El Khannoussi; M Amrani; H Errihani
Journal:  J Gastrointest Cancer       Date:  2012-03

3.  CHALLENGES OF AN OVARIAN NEUROENDOCRINE METASTASIS OF ADVANCED SMALL-CELL LUNG CARCINOMA - LITERATURE REVIEW AND CASE REPORT.

Authors:  V N Varlas; G Angelescu; Y Rhazi; B A Năsui; A L Pop; M L Gheorghiu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  Desmoplastic small round cell tumour in a young woman with widespread metastasis and peritoneal caking.

Authors:  Vidya Monappa; Sudha S Bhat; Manna Valiathan
Journal:  J Clin Diagn Res       Date:  2013-12-15

5.  A case of long-term survival of metastatic desmoplastic small round cell tumor treated with multimodal therapy.

Authors:  Tsubasa Watanabe; Shin'ichi Miyamoto; Koji Kitagori; Takahiro Horimatsu; Shuko Morita; Yoko Mashimo; Yasumasa Ezoe; Manabu Muto; Tsutomu Chiba
Journal:  Oncol Lett       Date:  2011-10-21       Impact factor: 2.967

Review 6.  Desmoplastic small round-cell tumour of the peritoneal cavity: case report and literature review.

Authors:  N Tsoukalas; M Kiakou; G Nakos; M Tolia; M Galanopoulos; K Tsapakidis; K Kamposioras; C Christofyllakis; G Dimitrakopoulos; D Sambaziotis
Journal:  Ann R Coll Surg Engl       Date:  2020-01-24       Impact factor: 1.891

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.